Abrysvo Or Arexvy Market 2026

Abrysvo Or Arexvy Market Size

The global Abrysvo or Arexvy market reached a value of nearly $1,545.60 million in 2024, having declined at a compound annual growth rate (CAGR) of -39.36% since 2019. The market is expected to decline from $1,545.60 million in 2024 to $1,379.89 million in 2029 at a rate of -2.24%. The market is then expected to grow at a CAGR of 4.97% from 2029 and reach $1,758.34 million in 2034. Growth in the historic period resulted from supportive government health policies, surge in respiratory infections, rise in seasonal vaccination demand and rising hospitalizations due to RSV. Factors that negatively affected growth in the historic period were vaccine hesitancy and side effect and awareness and perception barriers. Going forward, increasing aging population, rising public health funding, public awareness campaigns and shift towards preventative healthcare will drive growth. Factor that could hinder the growth of the Abrysvo or Arexvy market in the future include were Impact Of trade war and tariff, uneven reimbursement policies and stringent regulatory requirements.

Abrysvo Or Arexvy Market Drivers

The key drivers of the abrysvo or arexvy market include: Increasing Aging population During the forecast period, the increasing aging population will propel the growth of the abrysvo or arexvy market. Older adults face heightened vulnerability to respiratory infections such as respiratory syncytial virus (RSV), with risks of hospitalization, complications, and mortality rising significantly with age. As global life expectancy increases and fertility rates continue to decline, societies are undergoing a demographic transition marked by a rapidly expanding share of people aged 60 years and above. This shift is placing pressure on healthcare systems to prioritize preventive measures that can reduce hospital admissions, lower treatment costs, and support healthy aging. Vaccines play a central role in this transition, offering protection that directly addresses the medical and economic challenges associated with an aging population. The growing recognition of the need for resilience in healthcare systems, particularly in low- and middle-income countries where the majority of older adults will reside, is further reinforcing the importance of broad immunization strategies. Therefore, the increasing aging population will drive the growth of the abrysvo or arexvy market during the forecast period.

Abrysvo Or Arexvy Market Restraints

The key restraints on the abrysvo or arexvy market include: Impact Of Trade War And Tariffs Impact of trade wars and tariffs is restricting the growth of the abrysvo or arexvy market during the forecast period. Rising protectionist policies and retaliatory tariffs on pharmaceutical products are increasing costs for vaccine manufacturers, particularly those that rely on cross-border supply chains for raw materials, active pharmaceutical ingredients (APIs), and finished products. Elevated import duties not only raise production expenses but also create pricing pressures, making vaccines less affordable in key international markets. Furthermore, uncertainty around changing trade policies disrupts long-term planning, deters foreign investment, and slows global expansion of RSV vaccines. Such barriers also risk reducing the availability of vaccines in lower-income countries, where affordability is highly sensitive to shifts in trade costs. Consequently, the impact of trade wars and tariffs is expected to restrain the growth of the abrysvo or arexvy market during the forecast period.

Abrysvo Or Arexvy Market Trends

Major trends shaping the abrysvo or arexvy market include: Global Prequalification Of Maternal Vaccines To Enhance Infant Immunization Coverage Major companies in the vaccine market are focusing on maternal immunization strategies to protect infants during the first six months of life, a period of heightened vulnerability to respiratory syncytial virus (RSV). These innovations emphasize improving infant health outcomes, reducing hospitalization rates, and expanding global access to preventive solutions in both developed and low-resource settings. For instance, in March 2025, the World Health Organization (WHO) prequalified Abrysvo, a maternal RSV vaccine developed by Pfizer Inc., a US-based global pharmaceutical company specializing in innovative medicines and vaccines. Abrysvo is designed to provide protection to infants by transferring antibodies from mother to child during pregnancy, thereby reducing the risk of severe RSV-related illness in early infancy. By securing WHO prequalification, Pfizer aims to facilitate broader procurement through United Nations agencies, accelerate integration into national immunization programs, and expand access to life-saving RSV protection across global markets. Regulatory Expansion Of Adult RSV Vaccines To Broaden Protection Across Age Groups Companies in the vaccine market are focusing on expanding their preventive solutions across different adult populations to address the rising burden of respiratory syncytial virus (RSV). These innovations emphasize broadening vaccine indications, enhancing accessibility, and targeting at-risk groups beyond the elderly. For instance, in May 2023, Pfizer Inc., a US-based global pharmaceutical company specializing in vaccines and innovative medicines, received U.S. FDA approval for Abrysvo, an RSV vaccine designed for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 years and older. In October 2024, the FDA further expanded the label to include adults aged 18 through 59 years who are at increased risk of RSV disease. By securing these approvals, Pfizer aims to widen its reach across multiple adult age segments, strengthen its leadership in RSV prevention, and deliver broader protection against a major seasonal respiratory illness.

Opportunities And Recommendations In The Abrysvo Or Arexvy Market

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the abrysvo or arexvy companies to focus on expanding maternal immunization and global access strategies, focus on expanding vaccine indications and adult population coverage, focus on advancing preventive solutions for high-risk adult populations, focus on expanding the respiratory syncytial virus (RSV) prevention segment, focus on expanding the older adults (60+ years) segment, expand in emerging markets, focus on strengthening multi-channel distribution networks, focus on value-based pricing to strengthen market position, strengthening abrysvo’s promotional strategy for market penetration and awareness growth, enhancing arexvy’s promotional approach for competitive differentiation and uptake optimization and focus on hospitals and healthcare providers to drive sustainable growth.